Trader Alert: Colgate-Palmolive Company (CL), SLM Corporation (SLM), Novavax, Inc. (NVAX)

Colgate-Palmolive Company (CL) grew with the stock adding 1.13% or $0.76 to close at $67.86 on active trading volume of 5.13M compared its three months average trading volume of 3.43M. The New York New York 10022 based company operating under the Personal Products industry has been trending up for the last 52 weeks, with the shares price now 7.93% up for the period and up by 3.7% so far this year. With price target of $72.2 and a 13.01% rebound from 52-week low, Colgate-Palmolive Company has plenty of upside potential, making it a hold with a view buy.

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

SLM Corporation (SLM) gained $0.08 to close the day at a new closing price of $11.04, a 0.73% increase in value from its previous closing price that moved the stock 116.9% above its 52 week low of $5.34. A total of 5.12M shares exchanged hands during the day compared with its three month average trading volume of 4.39M. The stock, which fluctuated between $10.87 and $11.16 during the day, currently situated -5.24% below its 52 week high. The stock is up by 1.28% in the past one month and up by 53.76% over the past three months. With a one year target estimate of $12.65 and RSI of 52.41, the stock still has upside potential, making it a hold for now.

SLM Corporation, together with its subsidiaries, operates as a saving, planning, and paying for education company in the United States. It offers private education loans to students and their families. The company also provides banking products, such as certificates of deposits, money market deposit accounts, and high yield savings accounts; and a consumer savings network that offers financial rewards on everyday purchases to help families save for college. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.

Novavax, Inc. (NVAX) shares were up in last trading by 3.65% to $1.42. It experienced lighter than average volume on day. The stock decreased in value by almost -0.7% over the past week and grew 1.43% in the past month. It is currently trading 5.08% above its 50 day moving average and -67.73% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -83.27% decrease in value from its one year high of $8.49. The RSI indicator value of 55.02, lead us to believe that it is a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Stocks in the Spotlight: Twenty-First Century Fox, Inc. (FOXA), Novavax, Inc. (NVAX), Tenet Healthcare Corp. (THC)

Twenty-First Century Fox, Inc. (FOXA) had a active trading with around 4.85M shares changing hands compared to its three month average trading volume of 11.03M. The stock traded at the price of $29.93 with -0.33% change on the day. The New York New York 10036 based company is currently trading 33.82% above its 52 week low of $22.66 and -3.49% below its 52 week high of $31.25. Both the RSI indicator and target price of 66.24 and $31.96 respectively, lead us to believe that it should be put on hold over the coming weeks.

Twenty-First Century Fox, Inc., together with its subsidiaries, operates as a diversified media and entertainment company in the United States, the United Kingdom, Continental Europe, Asia, Latin America, and internationally. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments. The company produces and licenses news, sports, movie, and general and factual entertainment programming for distribution primarily through cable television systems, direct broadcast satellite operators, telecommunications companies, and online video distributors. It also broadcasts network programming; and operates 28 broadcast television stations, including 11 duopolies in the United States. In addition, the company produces and acquires live-action and animated motion pictures for distribution and licensing in various formats and entertainment media, as well as produces and licenses television programming worldwide. Further, it offers video advertising services, including consumer engagement and on-demand marketing campaigns; and operates two San Francisco-Bay area television stations. The company was formerly known as News Corporation. Twenty-First Century Fox, Inc. was founded in 1922 and is headquartered in New York, New York.

Novavax, Inc. (NVAX) continued its downward trend with the stock declining -4.2% or $-0.06 to close the day at $1.37 on light trading volume of 4.85M shares, compared to its three month average trading volume of 8.09M. The Gaithersburg Maryland 20878 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -78.96%, compared to the industry which has advanced 3.14% over the same period. With RSI of 50.27, the stock should still continue to rise and get closer to its one year target estimate of $3.29, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Tenet Healthcare Corp. (THC) shares were up in last trading by 4.23% to $18.99. It experienced higher than average volume on day. The stock increased in value by almost 10.09% over the past week and grew 32.06% in the past month. It is currently trading 18.34% above its 50 day moving average and -21.55% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -44.28% decrease in value from its one year high of $34.08. The RSI indicator value of 75.96, lead us to believe that it may reverse gains in the near term.

Tenet Healthcare Corp., together with its subsidiaries, primarily operates acute care hospitals and related healthcare facilities. The company operates through three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive, critical, and coronary care units; physical therapy, orthopedic, oncology, and outpatient services; tertiary care services, including open-heart surgery, neonatal intensive care, and neurosciences; quaternary care services for heart, liver, kidney, and bone marrow transplants; quaternary pediatric and burn services; gamma-knife brain surgery; and cyberknife radiation therapy for tumors and lesions in the brain, lung, neck, and spine. In addition, it offers clinical research programs related to cardiovascular and pulmonary diseases, musculoskeletal disorders, neurological disorders, genitourinary diseases, and various cancers, as well as drug and medical device studies. Further, the company operates freestanding ambulatory surgery and imaging centers, short-stay surgical facilities, and Aspen’s hospitals and clinics. Additionally, it offers operational management for patient access, accounts receivable management, health information management, revenue integrity, and patient financial services; communications and engagement solutions; and clinical integration, financial risk management, and population health management services. As of December 31, 2015, the company operated 86 hospitals, 20 short-stay surgical hospitals, and approximately 475 outpatient centers; and 9 private hospitals and clinics, as well as 249 ambulatory surgery, 20 imaging, and 35 urgent care centers in the United Kingdom. Tenet Healthcare Corp. was founded in 1967 and is headquartered in Dallas, Texas.

 

Stocks In Queue: Visa Inc. (V), AbbVie Inc. (ABBV), Novavax, Inc. (NVAX)

Visa Inc. (V) fell -0.25% during last trading as the stock lost $-0.2 to finish the day at $81.17 with about 7.29M shares changing hands, compared to its three month average trading volume of 10.51M. The $189.34B market cap company, which fluctuated between $80.79 and $81.85 during the day, currently situated 23.7% above its 52 week low of $66.12 and -3.12% away from its one year high of $83.96. The RSI of 59.71 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Visa Inc. operates as a payments technology company worldwide. The company facilitates commerce through the transfer of value and information among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a processing network that enables authorization, clearing, and settlement of payment transactions; and offers fraud protection for account holders and assured payment for merchants. The company also offers gateway services for merchants to accept, process, and reconcile payments; manage fraud; and safeguard payment security online, as well as processing services for participating issuers of visa debit, prepaid, and ATM payment products. In addition, it provides digital products, including Visa Checkout that offers consumers an expedited and secure payment experience for online transactions; and Visa Direct, a push payment product platform, which facilitates payer-initiated transactions that are sent directly to the Visa account of the recipient, as well as Visa token service that replaces the card account numbers from the transaction with a token. Further the company offers corporate (travel) and purchasing card products, as well as value-added services. It provides its services under the Visa, Visa Electron, Interlink, V PAY, and PLUS brands. The company has a strategic partnership agreement with Oman Arab Bank to convert the bank’s current electron cards to chip-and-PIN debit cards. Visa Inc. was incorporated in 2007 and is headquartered in San Francisco, California.

AbbVie Inc. (ABBV) gained $0.71 to close the day at a new closing price of $61.99, a 1.16% increase in value from its previous closing price that moved the stock 26.92% above its 52 week low of $51.6. A total of 7.28M shares exchanged hands during the day compared with its three month average trading volume of 8.08M. The stock, which fluctuated between $61.05 and $62.41 during the day, currently situated -7.23% below its 52 week high. The stock is up by 1.01% in the past one month and up by 2.4% over the past three months. With a one year target estimate of $70.11 and RSI of 49.91, the stock still has upside potential, making it a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Novavax, Inc. (NVAX) had a light trading with around 7.07M shares changing hands compared to its three month average trading volume of 8.13M. The stock traded between $1.41 and $1.47 before closing at the price of $1.43 with -1.38% change on the day. The Gaithersburg Maryland 20878 based company is currently trading 23.28% above its 52 week low of $1.16 and -83.16% below its 52 week high of $8.49. Both the RSI indicator and target price of 55.74 and $3.29 respectively, lead us to believe that it should be put on hold over the coming weeks.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Traders Watch list: Novavax, Inc. (NVAX), Ocwen Financial Corporation (OCN), Abbott Laboratories (ABT)

Novavax, Inc. (NVAX) saw its value increase by 7.41% as the stock gained $0.1 to finish the day at a closing price of $1.45. The stock was higher in trading and has fluctuated between $1.16-$8.49 per share for the past year. The shares, which traded within a range of $1.31 to $1.46 during the day, are down by -10.49% in the past three months and down by -80.79% over the past six months. It is currently trading 7.49% above its 20 day moving average and 7.2% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $3.29 a share over the next twelve months. The current relative strength index (RSI) reading is 57.27.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Ocwen Financial Corporation (OCN) shares were down in last trading by -13.08% to $5.05. It experienced higher than average volume on day. The stock decreased in value by almost -12.02% over the past week and fell -7.85% in the past month. It is currently trading -2.78% below its 50 day moving average and 55.96% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -26.49% decrease in value from its one year high of $6.41. The RSI indicator value of 40.52, lead us to believe that it is a hold for now.

Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Its Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset management services to owners of mortgage loans and foreclosed real estate. This segment’s residential servicing portfolio includes conventional, government insured, and non-agency loans. The company’s Lending segment originates and purchases conventional and government-insured residential forward and reverse mortgage loans primarily through its correspondent lending arrangements, broker relationships, and directly with mortgage customers. Ocwen Financial Corporation was founded in 1988 and is headquartered in West Palm Beach, Florida.

Abbott Laboratories (ABT) traded within a range of $40.31 to $40.79 after opening the day at $40.79. The company has seen its stock increase in value by 6.7% so far this year. The stock was down close to -0.88% on light volume in last trading session and closed at $40.72 per share. After the recent fall, the stock is currently holding -9.93% below its 52 week high of $45.79 and 15.98% above its 12-month low of $36. The shares are up by over 0.01% in the last three months, and the RSI indicator value of 65.41 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. In addition, it develops cardiovascular medical devices. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

 

Stocks Alert: Oracle Corporation (ORCL), Novavax, Inc. (NVAX), Sprint Corporation (S)

Oracle Corporation (ORCL) grew with the stock adding 1.16% or $0.45 to close at $39.11 on light trading volume of 10.37M compared its three months average trading volume of 12.78M. The Redwood City California 94065 based company operating under the Application Software industry has been trending up for the last 52 weeks, with the shares price now 12.26% up for the period and up by 2.11% so far this year. With price target of $44 and a 19.85% rebound from 52-week low, Oracle Corporation has plenty of upside potential, making it a hold with a view buy.

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It offers services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service. The company licenses its Oracle Database software, which enables storage, retrieval, and manipulation of various forms of data; and Oracle Fusion Middleware software to build, deploy, secure, access, and integrate business applications, as well as automate their business processes. It also provides a range of software for mobile computing to address the development needs of businesses; and Java, a software development language. In addition, the company offers application software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific application software. Further, it offers hardware systems products, such as Oracle Engineered Systems, servers, storage, networking, industry specific hardware, virtualization software, operating systems, management software, and related hardware services. Additionally, the company offers customers with rights to software product upgrades and maintenance releases, patches released, and Internet access to technical content, as well as Internet and telephone access to technical support personnel. The company also provides consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.

Novavax, Inc. (NVAX) dropped $-0.08 to close the day at a new closing price of $1.35, a -5.59% decrease in value from its previous closing price that moved the stock 16.38% above its 52 week low of $1.16. A total of 10.36M shares exchanged hands during the day compared with its three month average trading volume of 8.19M. The stock, currently situated -84.1% below its 52 week high. The stock is down by -7.53% in the past one month and down by -23.73% over the past three months. With a one year target estimate of $3.29 and RSI of 49.43, the stock still has upside potential, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Sprint Corporation (S) shares were down in last trading by -1.48% to $8.63. It experienced lighter than average volume on day. The stock decreased in value by almost -1.82% over the past week and grew 1.77% in the past month. It is currently trading 10.19% above its 50 day moving average and 50.7% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -4.11% decrease in value from its one year high of $9. The RSI indicator value of 57.38, lead us to believe that it is a hold for now.

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells wireless devices, broadband devices, connected devices, and accessories to agents and other third-party distributors. The Wireline segment provides wireline voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies, and targeted business and consumer subscribers, as well as for cable multiple system operators. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

 

Traders Recap: Novavax, Inc. (NVAX), Medtronic plc (MDT), Activision Blizzard, Inc. (ATVI)

Novavax, Inc. (NVAX) continued its upward trend with the stock climbing 0.7% or $0.01 to close the day at $1.43 on lower than average trading volume of 7.77M shares, compared to its three month average trading volume of 8.21M. The Gaithersburg Maryland 20878 based company has been outperforming the biotechnology companies by -23.9968% for last three months and its recent losses have trimmed gains to 13.49% YTD, versus the biotechnology industry which is up 3.62% for the same period. The RSI of 53.52 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Medtronic plc (MDT) had a active trading with around 7.67M shares changing hands compared to its three month average trading volume of 6.62M. The stock traded between $74.12 and $75.27 before closing at the price of $74.9 with 1.46% change on the day. The Dublin Dublin 2 based company is currently trading 8% above its 52 week low of $69.35 and -16.1% below its 52 week high of $89.27. Both the RSI indicator and target price of 56.46 and $84.55 respectively, lead us to believe that it should be put on hold over the coming weeks.

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

Activision Blizzard, Inc. (ATVI) opening the day at $37.67. The company has seen its stock increase in value by 6.29% so far this year. The stock was up close to 1.8% on light volume in last trading session and closed at $38.38 per share. After the recent gain, the stock is currently holding -15.74% below its 52 week high of $45.55 and 46.06% above its 12-month low of $26.49. The shares are down by over -12.35% in the last three months, and the RSI indicator value of 58.8 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Activision Blizzard, Inc. develops and publishes online, personal computer (PC), video game console, handheld, mobile, and tablet games. The company operates through two segments, Activision Publishing, Inc. and Blizzard Entertainment, Inc. The company develops, publishes, and sells interactive software products and content through retail channels or digital downloads; and downloadable content to a range of gamers. It also publishes subscription-based massively multiplayer online role-playing games; and strategy and role-playing games. In addition, the company maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games. Further, it engages in creating original film and television content; and provides warehousing, logistical, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, game specialty stores, and consumers through third-party distribution, licensing arrangements, and direct digital purchases in the United States, Canada, Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, the Netherlands, Australia, South Korea, China, and internationally. Activision Blizzard, Inc. is headquartered in Santa Monica, California.

 

Stocks Under Review: Marathon Petroleum Corporation (MPC), Novavax, Inc. (NVAX), Cliffs Natural Resources Inc. (CLF)

Marathon Petroleum Corporation (MPC) continued its downward trend with the stock declining -1.81% or $-0.91 to close the day at $49.46 on active trading volume of 8.04M shares, compared to its three month average trading volume of 6.29M. The Findlay Ohio 45840 based company has been outperforming the oil & gas refining & marketing group over the past 52 weeks, with the stock gaining 11.05%, compared to the industry which has advanced 5.64% over the same period. With RSI of 52.38, the stock should still continue to rise and get closer to its one year target estimate of $60.35, making it a hold for now.

Marathon Petroleum Corporation, together with its subsidiaries, engages in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Speedway, and Midstream. The company refines crude oil and other feed stocks at its seven refineries in the Gulf Coast and Midwest regions of the United States; and purchases ethanol and refined products for resale. Its refined products include gasoline, distillates, propane, feed stocks and special products, heavy fuel oil, and asphalt. The company also sells transportation fuels and convenience products in the retail market through Speedway convenience stores; and transports crude oil and other feed stocks to its refineries and other locations. Marathon Petroleum Corporation markets its refined products to resellers, consumers, independent retailers, wholesale customers, marathon-branded independent entrepreneurs, its Speedway convenience stores, airlines, transportation companies, and utility companies, as well as exports its refined products. As of December 31, 2015, it owned, leased, and had ownership interests in approximately 8,400 miles of crude oil and refined product pipelines, as well as owned and operated 2,766 gasoline and convenience stores in 22 states of the United States; and had 5,600 retail outlets operated by independent entrepreneurs in 19 states in the United States. The company was incorporated in 2009 and is headquartered in Findlay, Ohio.

Novavax, Inc. (NVAX) grew with the stock adding 3.65% or $0.05 to close at $1.42 on light trading volume of 7.86M compared its three months average trading volume of 8.41M. The Gaithersburg Maryland 20878 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -79.92% down for the period and up by 12.7% so far this year. With price target of $3.29 and a 22.41% rebound from 52-week low, Novavax, Inc. has plenty of upside potential, making it a hold with a view buy.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Cliffs Natural Resources Inc. (CLF) continued its downward trend with the stock declining -0.47% or $-0.04 to close the day at $8.43 on higher than average trading volume of 7.84M shares, compared to its three month average trading volume of 13.57M. The Cleveland Ohio 44114 based company has been outperforming the industrial metals & minerals companies by 50.4132% for last three months and its recent gains have pushed the stock slightly up 0.24% YTD, versus the industrial metals & minerals industry which is up 2.89% for the same period. The RSI of 47.01 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Cliffs Natural Resources Inc., a mining and natural resources company, produces and supplies iron ore. The company operates five iron ore mines in Michigan and Minnesota; and Koolyanobbing iron ore mining complex located in Western Australia, which produces lump and fines iron ore. It also own two iron ore mines in Eastern Canada. Cliffs Natural Resources Inc. sells its iron products to integrated steel companies and steel producers in the United States, China, Canada, and internationally. The company was formerly known as Cleveland-Cliffs Inc. Cliffs Natural Resources Inc. was founded in 1847 and is headquartered in Cleveland, Ohio.

 

Stocks Highlights: Exelon Corporation (EXC), Novavax, Inc. (NVAX), The Blackstone Group L.P. (BX)

Exelon Corporation (EXC) had a active trading with around 6.32M shares changing hands compared to its three month average trading volume of 6.19M. The stock traded between $35.32 and $36.21 before closing at the price of $36.08 with 1.63% change on the day. The Chicago Illinois 60680 based company is currently trading 42.69% above its 52 week low of $26.26 and -2.47% below its 52 week high of $37.7. Both the RSI indicator and target price of 62.54 and $37.69 respectively, lead us to believe that it should be put on hold over the coming weeks.

Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States and Canada. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, as well as wind and solar facilities. The company also sells renewable energy and other energy-related products and services; and engages in natural gas and oil exploration and production activities, as well as sells electricity and natural gas to wholesale and retail customers. In addition, it is involved in the purchase and regulated retail sale of electricity, and the provision of electricity transmission and distribution services to retail customers in northern Illinois, southeastern Pennsylvania, and central Maryland. Further, the company engages in the purchase and regulated retail sale of natural gas, and the provision of gas distribution services to retail customers in the Pennsylvania counties surrounding the City of Philadelphia, as well as in central Maryland, including the City of Baltimore. It serves distribution utilities, municipalities, cooperatives, and financial institutions, as well as commercial, industrial, governmental, and residential customers. The company was founded in 1887 and is headquartered in Chicago, Illinois.

Novavax, Inc. (NVAX) continued its upward trend with the stock climbing 3.79% or $0.05 to close the day at $1.37 on light trading volume of 6.17M shares, compared to its three month average trading volume of 8.52M. The Gaithersburg Maryland 20878 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -80.2%, compared to the industry which has dropped -1.38% over the same period. With RSI of 51.75, the stock should still continue to rise and get closer to its one year target estimate of $3.29, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

The Blackstone Group L.P. (BX) shares were up in last trading by 0.3% to $30.51. It experienced higher than average volume on day. The stock increased in value by almost 12.38% over the past week and grew 14.92% in the past month. It is currently trading 14.57% above its 50 day moving average and 17.98% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -0.39% decrease in value from its one year high of $30.91. The RSI indicator value of 70.55, lead us to believe that it may reverse gains in the near term.

The Blackstone Group L.P. is a publicly owned hedge fund sponsor. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations, retirees, sovereign wealth funds, and institutional and individual investors. The firm manages separate client focused portfolios for its clients. It launches fixed income mutual funds. The firm also launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients. It invests in private equity, public equity, fixed income, and alternative investment markets. The Blackstone Group L.P. was founded in 1985 and is based in New York, New York with additional offices in London, United Kingdom, Hong Kong, Beijing, China, Dubai, UAE, Dusseldorf, Germany, Los Angeles, Santa Monica, Mexico City, Mexico, Paris, France, Sao Paulo, Brazil, Seoul, Korea, Shanghai, China, Singapore, Sydney, Australia, Copenhagen, Denmark, and Tokyo, Japan.

 

3 Notable Runners: The Bank of New York Mellon Corporation (BK), Novavax, Inc. (NVAX), Ally Financial Inc. (ALLY)

The Bank of New York Mellon Corporation (BK) failed to extend gains with the stock declining -1.27% or $-0.62 to close the day at $48.09 on lower than average trading volume of 5.29M shares, compared to its three month average trading volume of 6.17M. The New York New York 10286 based company has been outperforming the asset management companies by 18.1797% for last three months and its recent gains have pushed the stock slightly up 1.5% YTD, versus the asset management industry which is up 3.24% for the same period. The RSI of 58.35 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

The Bank of New York Mellon Corporation, an investment company, provides financial products and services to institutions, corporations, and high net worth individuals in the United States and internationally. It operates through two segments, Investment Management and Investment Services. The company offers investment management; trust and custody; foreign exchange; fund administration; global collateral services; securities lending; depositary receipts; corporate trust; global payment/cash management; banking services; and clearing services. It also provides mutual funds, separate accounts, wealth management and private banking services; and broker-dealer services, registered investment advisory services, prime brokerage services, and working capital solutions. In addition, the company is involved in credit-related activities, business exits, leasing operations, and corporate treasury activities; and the provision of global markets and institutional banking services. The Bank of New York Mellon Corporation was founded in 1784 and is headquartered in New York, New York.

Novavax, Inc. (NVAX) had a light trading with around 5.26M shares changing hands compared to its three month average trading volume of 8.65M. The stock traded between $1.3 and $1.34 before closing at the price of $1.32 with 0.76% change on the day. The Gaithersburg Maryland 20878 based company is currently trading 13.79% above its 52 week low of $1.16 and -84.45% below its 52 week high of $8.49. Both the RSI indicator and target price of 47.88 and $3.29 respectively, lead us to believe that it should be put on hold over the coming weeks.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Ally Financial Inc. (ALLY) traded within a range of $19.48 to $19.85 after opening the day at $19.54. The company has seen its stock increase in value by 3.68% so far this year. The stock was up close to 0.1% on active volume in last trading session and closed at $19.72 per share. After the recent gain, the stock is currently holding -4.27% below its 52 week high of $20.6 and 35.53% above its 12-month low of $14.55. The shares are down by over -1.3% in the last three months, and the RSI indicator value of 56.87 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Ally Financial Inc., a diversified financial services company, provides a range of financial products and services primarily to automotive dealers and their retail customers in the United States. It offers dealer financial services, including a range of financial services and insurance products to automotive dealers and retail customers. The company also provides automotive finance services for dealers, such as new and used vehicle inventory financing; inventory insurance; term loans, including real estate and working capital loans; and vehicle remarketing services, as well as vehicle service contracts (VCSs) and guaranteed automobile protection (GAP) products. In addition, it offers retail automotive financing for new and used vehicles, and leasing for new vehicles; consumer finance protection and insurance products, such as VSCs, maintenance coverage, and GAP products; commercial insurance products; and senior secured commercial-lending products. Further, the company, through its subsidiary, Ally Bank provides savings and money market accounts, certificates of deposit, interest-bearing checking accounts, trust accounts, and individual retirement accounts; and online and mobile banking, electronic bill pay, remote deposit, and electronic funds transfer. It also engages in the management of held-for-investment mortgage loan portfolio that includes the execution of bulk purchases of jumbo and low-to-moderate income mortgage loans originated by third parties. The company was formerly known as GMAC Inc. and changed its name to Ally Financial Inc. in May 2010. Ally Financial Inc. was founded in 1919 and is based in Detroit, Michigan.

 

Stocks in Review: Corning Incorporated (GLW), Clovis Oncology, Inc. (CLVS), Novavax, Inc. (NVAX)

Corning Incorporated (GLW) traded within a range of $24.38 to $24.64 after opening the day at $24.38. The company has seen its stock increase in value by 0.78% so far this year. The stock was up close to 0.66% on light volume in last trading session and closed at $24.46 per share. After the recent gain, the stock is currently holding -3.51% below its 52 week high of $25.35 and 55.6% above its 12-month low of $16.13. The shares are up by over 5.09% in the last three months, and the RSI indicator value of 57.33 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials worldwide. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for liquid crystal displays (LCDs) used in LCD televisions, notebook computers, and flat panel desktop monitors. The Optical Communications segment manufactures optical fiber and cable; and hardware and equipment products comprising cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories. This segment also offers subscriber demarcation, connection and protection devices, passive solutions, and outside plant enclosures; and coaxial RF interconnects for the cable television industry and microwave applications. The Environmental Technologies segment manufactures ceramic substrates and filter products for emissions control in mobile and stationary, and gasoline and diesel applications. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals. The Life Sciences segment manufactures and supplies scientific laboratory products consisting of consumables, such as plastic vessels, specialty surfaces, and media, as well as general labware and equipment for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry. It also engages in a pharmaceutical glass vessel and a tubing business; and precision materials’ non-LCD business, as well as precision laser cutting/shaping technologies, and flow reactors and adjacency businesses for glass. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

Clovis Oncology, Inc. (CLVS) managed to rebound with the stock climbing 4% or $1.72 to close the day at $44.67 on active trading volume of 6.48M shares, compared to its three month average trading volume of 2.37M. The Boulder Colorado 80301 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 40.91%, compared to the industry which has dropped -3.72% over the same period. With RSI of 66.68, the stock should still continue to rise and get closer to its one year target estimate of $46.89, making it a hold for now.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast cancers. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Novavax, Inc. (NVAX) gained $0.04 to close the day at a new closing price of $1.31, a 3.15% increase in value from its previous closing price that moved the stock 12.93% above its 52 week low of $1.16. A total of 6.46M shares exchanged hands during the day compared with its three month average trading volume of 8.73M. The stock, which fluctuated between $1.27 and $1.32 during the day, currently situated -84.57% below its 52 week high. The stock is up by 5.65% in the past one month and down by -34.5% over the past three months. With a one year target estimate of $3.29 and RSI of 49.55, the stock still has upside potential, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.